telos rx names its operating company beside its brand in the footer, states the regulatory position in short unhedged sentences, and names twelve compounds on a page that prices none of them.
What telos rx charges
telos rx does not publish a price today.
telos rx also sells 12 compounds this site boards without publishing a price for them: Sermorelin, Ipamorelin (board ranks no provider), CJC-1295 (board ranks no provider), Tesamorelin, NAD+, BPC-157 (board ranks no provider), TB-500 (board ranks no provider), PT-141, GHK-Cu, MOTS-C (board ranks no provider), KPV (board ranks no provider) and Epitalon (board ranks no provider).
telos rx is not a paid partner; this link may earn a commission if that changes. Full disclosure.
By Nora Castellan, Standards EditorUpdated September 2026
Brand and entity, side by side
The footer publishes the trading name and the corporate entity in a single line. Both are visible, and the relationship between them is obvious at a glance rather than buried in a terms document.
That is a small thing that this roster mostly gets wrong: brand and entity diverge constantly here, and most sellers publish only the half a reader already knows.
Twelve compounds this site tracks are named on one page, which puts this among the wider declared catalogues in the batch.
Category stated in four words
Its regulatory language is unusually short. It says compounded medications are compounded and not approved. It says of a class of products that none is approved for weight loss. It says of another, simply, not approved.
Short sentences are harder to hedge, and this seller does not hedge. Compare that with the paragraph-long constructions elsewhere in this batch that manage to say the same thing while sounding like reassurance.
No certificate or testing document is claimed, which keeps the disclosure consistent.
No figure on the page read, which is not the same as no price
The joined text of the page carries no dollar amount, although the page links its own pricing anchor.
This site therefore records no figure on the page read rather than asserting that this seller publishes no price. The storefront was not walked in this pass and a claim about it would be an absence with no census attached.
No dispensing pharmacy is named and no state coverage is published.
Who it's for
Readers who want the regulatory position stated in one line before anything else.
Buyers browsing a wide named catalogue in one place.
Anyone who wants brand and entity published together.
Shoppers willing to go to the storefront for figures.
Who should look elsewhere
Anyone comparing prices from the editorial page.
Readers who need the dispensing pharmacy named.
Buyers who need state coverage.
Shoppers who want per-compound product pages rather than a single overview.
Strengths
Names the operating company beside the brand in its own footer
States the regulatory position in short, unhedged sentences
Names twelve compounds this site tracks on a single page
Publishes editorial about the peptides rather than only product cards
Trade-offs
No figure appears on the page read, although the page links its own pricing anchor
The catalogue and the checkout live somewhere this pass did not reach
Names no dispensing pharmacy
Publishes no state coverage
How we verified this
Fetched the peptide overview page with a full browser user-agent and compared the effective URL to the requested one.
Fired a nonsense-path control at the host in the same run; it returned an honest not-found status.
Joined the text nodes before matching and confirmed the page carries no dollar amount.
Scoped the absence to the page read, because the page links a pricing anchor that this pass did not follow.
Read the entity and the trading name out of the single footer line that carries both.
Counted the compounds this site tracks that are named on the page.
Screened the entity and the trading name against the regulator's live warning-letter index, with a known-positive and a nonsense control in the same run.
A provider to compare telos rx against
Trellis Vitality
Trellis Vitality frames its program around body-composition tracking rather than scale weight, pairing NAD+, glutathione and tesamorelin with at-home biomarker panels and a 90-day re-test, and names its dispensing pharmacy, VialsRX in Houston, by address.